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PTPN2 (protein tyrosine phosphatase nonreceptor type 2) 
and the presence of the CD-associated variations within 
these genes results in similar effects. Taken together, more 
and more evidence suggests a close functional correlation 
between loss of tolerance and defective autophagy in CD 
patients. Therefore, most likely, the onset of CD is triggered 
by both a loss of tolerance as well as a dysfunction of au-
tophagy, which finally results in the onset of chronic intesti-
nal inflammation.  © 2014 S. Karger AG, Basel 
 Introduction 
 Along with ulcerative colitis (UC), Crohn’s disease 
(CD) is one of the major forms of inflammatory bowel 
disease (IBD). The interplay between environmental fac-
tors, genetic predisposition, intestinal microbiota as well 
as the innate and adaptive immune system needs to be 
tightly controlled. An imbalance in these factors predis-
poses to the pathogenesis of IBD. Current hypotheses 
suggest that an epithelial barrier defect coupled with an 
impaired immune response of the innate as well as adap-
tive immune system to the commensal flora results in ei-
ther excessive upregulation or impaired suppression of 
inflammatory responses, finally leading to chronic intes-
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 Abstract 
 Crohn’s disease (CD) is characterized by a breakdown of the 
intestinal epithelial barrier function leading to an uncon-
trolled immune response to bacterial antigens. Available 
data demonstrate that appropriate response and early host 
defense against invading bacteria are crucial to maintain tol-
erance towards commensal bacteria. When the mechanisms 
of early removal of invading bacteria are disturbed, a loss of 
tolerance and a full-blown adaptive immune reaction, which 
is mounted against the usually harmless commensal flora, 
are induced. Dysfunction of autophagy caused by genetic 
variations within CD susceptibility genes, such as ATG16L1 
and IRGM, results in defective handling of intracellular and 
invading bacteria and causes prolonged survival and defec-
tive clearance of those microbes. Dysfunction of ATG16L1 
and IRGM has also been shown to cause aberrant Paneth cell 
function and uncontrolled secretion of proinflammatory cy-
tokines finally resulting in increased susceptibility to bacte-
rial infection and the onset of colitis. Interestingly, autopha-
gy can also be regulated by other CD susceptibility genes, 
such as NOD2 (nucleotide oligomerization domain 2) or 
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tinal inflammation  [1] . Current studies suggested that in-
testinal microbial diversity is reduced and species com-
position is altered, especially in CD: Firmicutes are re-
duced while Bacteroidetes and Enterobacteriaceae are 
increased in the intestine of CD patients  [2, 3] . Genome-
wide association studies identified genetic variations in 
163 genes which are associated with IBD, including 110 
loci shared by both disease subtypes, 30 loci classified as 
specific for CD and 23 as specific for UC  [4] . Of note, 
members of the innate immune system, such as the intra-
cellular bacterial-sensor NOD2 (nucleotide oligomeriza-
tion domain 2) as well as the autophagy genes ATG16L1 
(autophagy-related gene 16-like 1) and IRGM (immuni-
ty-related GTPase family M), are exclusively associated 
with CD  [4] .
 CD – Loss of Tolerance? 
 Immune cells trigger an effective inflammatory re-
sponse as soon as pathogen-associated molecular pat-
terns (PAMPs) are present. In the gut, however, myriads 
of commensal bacteria or food antigens do normally not 
provoke adverse reactions. This seems to be due to active 
tolerance induction by intestinal epithelial cells (IECs) 
and specific immune cell subsets. IECs secrete mucins 
and antimicrobial molecules to limit the number of com-
mensals directly penetrating the gut mucosa  [5] . In CD, 
this barrier is impaired and increased translocation of 
bacteria and food antigens provokes an enhanced proin-
flammatory response of the innate as well as adaptive im-
mune system, which finally results in loss of tolerance to-
wards commensal antigens  [6, 7] . 
 Intestinal Macrophages 
 Myeloid intestinal immune cells, such as intestinal 
macrophages (iMACs) and dendritic cells (DCs) – in 
contrast to macrophages/DCs in other tissues, display a 
hypo-responsive, tolerance-inducing phenotype  [8] . 
iMACs from CD patients, however, display a significant-
ly higher expression of CD14, CD16, HLA-DR, CD11b, 
and CD11c, indicating additional macrophage popula-
tions in the inflamed mucosa, which reflects either a re-
cruitment of new cells from the blood or a phenotypic 
change in resident cells  [9, 10] . Under normal conditions, 
iMACs can eliminate intracellular bacteria without pro-
voking an immune reaction  [11] . They sample the lumi-
nal content and, by expression of specific surface markers 
and cytokine secretion, induce tolerogenic T cells  [8] . 
These iMACs from normal mucosa rarely express the co-
stimulatory molecules CD80 and CD86. In CD, a macro-
phage population is found with high expression of co-
stimulatory molecules, which is presumably responsible 
for the perpetuated immune response  [12] . This special 
population of CD iMACs also reveals increased activa-
tion of nuclear factor (NF)-κB in the inflamed mucosa 
 [13] , which might, at least in part, be due to decreased 
levels of human glucocorticoid receptor in mucosal CD 
iMACs and lead to decreased protection against NF-κB 
action  [14] . Further, NADPH oxidase mRNA is down-
regulated or absent in macrophages from normal muco-
sa, which correlates with a lack of oxidative burst activity. 
In CD, however, macrophage oxidative burst activity is 
increased and NADPH oxidase mRNA is induced  [15] . 
CD iMACs also display increased expression of TLR2 and 
TLR4, which likely contributes to their increased activa-
tion status in response to PAMPs. The absence of TLRs 
abolishes the reactivity of mucosal macrophages to bacte-
rial wall products, while the presence of TLRs might con-
tribute to the inflammatory process  [16] . Of note, the 
chaperone molecule glycoprotein gp96 links the adaptive 
with the innate immune system. During cellular stress, 
peptide-loaded gp96 can be released and presented to T 
cells by antigen-presenting cells. gp96 is induced during 
differentiation of normal iMACs but is not detected in 
iMACs in CD mucosa. As gp96 has been described as hav-
ing a role in tolerance induction, this may be relevant for 
loss of tolerance against luminal bacteria found in CD 
patients  [17] . Further, a reduced expression of subunits 
of the ubiquitin-proteasome system in iMACs of normal 
mucosa supports the concept of the presence of a nonre-
active, anergic macrophage phenotype in the gut under 
normal conditions. Reinduction in iMACs of IBD mu-
cosa reflects activated iMACs which can present antigen-
ic peptides and thus support inflammation  [18] .
 Immune Cells and Pattern Recognition Receptors 
 As it is the case for IECs, NOD2 malfunction in DCs 
and iMACs results in poor bacterial clearance  [6, 19] and 
consequently in prolonged bacterial infection and hyper-
activation of the immune system  [20] , finally promoting 
the secretion of proinflammatory cytokines and an im-
mune-activating phenotype. NLRP3 and NLRP6 are able 
to form multiprotein complexes called inflammasomes, 
which are important for processing pro-IL-1β and pro-
IL-18 into their mature forms and their final secretion 
 [21] . Low-level inflammasome activation and IL-18 se-
cretion is essential for wound healing and repair in the 
D
ow
nl
oa
de
d 
by
: 
Un
ive
rs
itä
t Z
ür
ich
,  
Ze
nt
ra
lb
ib
lio
th
ek
 Z
ür
ich
   
   
   
 
13
0.
60
.4
7.
22
 - 
6/
3/
20
16
 5
:2
2:
03
 P
M
 Spalinger  /Rogler  /Scharl  
 
Dig Dis 2014;32:370–377
DOI: 10.1159/000358140
372
intestines  [21] . Physiologic NLRP3 and NLRP6 activity is 
involved in shaping the composition of the intestinal mi-
crobiota  [22, 23] . However, uncontrolled inflammasome 
activity results in enhanced proinflammatory responses 
and proliferation of destructive immune cells  [21] . 
 Several proteins are involved in the modulation of in-
tracellular signaling pathways downstream of pattern 
recognition receptors and the outcome of the resulting 
immune response. The CD risk gene PTPN2 (protein ty-
rosine phosphatase nonreceptor type 2)  [24] negatively 
controls the activation of proinflammatory signaling 
 cascades  [25, 26] . If PTPN2 is lost or – as in some CD pa-
tients – malfunctioning, it results in hyperactivation of 
monocytes by bacterial products  [27] and increased re-
sponses to the proinflammatory cytokines TNF and 
IFN-γ  [26, 28] . Finally, an inflammatory response with 
increased levels of IL-6, IL-12, and IFN-γ as well as a loss 
of intestinal barrier function is the result, leading to the 
breakdown of tolerance mechanisms  [26] . PTPN22 also 
controls bacterial-induced signaling cascades  [29] and a 
variant within the PTPN22 gene locus protects from CD 
 [30] . In CD, intestinal levels of PTPN22 are reduced, re-
sulting in enhanced secretion of IL-6 but reduced IL-12 
secretion  [31] . This leads to a skewed response to patho-
gens inducing a cytokine profile favoring pathogenic 
Th17 cell proliferation.
 At a functional level, alterations in pattern recognition 
receptor signaling in innate immune cells result in the 
aberrant induction of adaptive immune responses. Dur-
ing intestinal inflammation, intestinal CD14+ cells se-
crete enhanced levels of IL-1β, IL-6, and IL-12 and thus 
promote the development of Th1 and Th17 cells  [32] . 
Th17 cells, which defend extracellular bacteria and fungi 
in healthy persons  [33] , are increased in IBD patients and 
play a major role in driving pathologic inflammation and 
tissue destruction in the intestine  [34] . In the intestinal T 
cell population, high proportions of so-called inducible 
regulatory T cells (T reg ) can be found  [35] . They actively 
downmodulate excessive activation of the adaptive im-
mune system. In contrast to natural T reg , inducible T reg s 
develop in the periphery upon antigen challenge and re-
lieve inflammatory reactions after antigen clearance fol-
lowing an infection  [36] . In the gut, microbial-specific 
inducible T reg s are believed to induce tolerance towards 
commensal microflora  [37] . In CD, however, this toler-
ance-inducing mechanism seems to be lost: The tight 
junctions between epithelial cells become leaky  [7] , and 
consequently increased numbers of commensal bacteria 
can penetrate the mucosa finally and thus increase NOD2 
activation  [6] . Further, high numbers of activated proin-
flammatory T cells can be found  [38] . Additionally, IL-10 
is an important regulatory cytokine able to suppress the 
synthesis of proinflammatory mediators, including IFN-γ 
and TNF, as well as costimulatory molecules and MHC 
class II molecules on antigen-presenting cells  [39] . T reg s 
and to a lower extent also Th2 cells produce IL-10 in order 
to downregulate proinflammatory responses and end an 
immune reaction restoring tolerance towards commensal 
bacteria  [39] . The importance of this tolerance-inducing 
functions of IL-10 is highlighted by the fact that loss of 
IL-10 results in spontaneous colitis in mice  [40] , and loss-
of-function variants in either IL-10 or IL-10 receptors re-
sult in severe, very-early-onset IBD  [41] . 
 CD – Dysfunction of Autophagy? 
 Autophagy is critically involved in regulating innate 
immune responses by providing a defense mechanism 
against intracellular microbial pathogens and mediating 
antigen presentation via MHC class II molecules  [42, 43] . 
Dysfunctional autophagy is associated with defective bac-
terial handling, prolonged intracellular survival of patho-
gens, and uncontrolled inflammation. Levels of autopha-
gy proteins, such as ATG16L1 or IRGM, are significantly 
decreased in the intestines of CD patients  [44] . To date, 
three autophagy genes have been confirmed as CD sus-
ceptibility genes, namely ATG16L1, IRGM, and LRRK2 
(leucine-rich repeat kinase 2)  [24, 45] . LRRK2-deficient 
mice are more susceptible to dextran sodium sulfate 
(DSS)-induced colitis, since LRRK2 inhibits activation of 
NFAT1, which promotes the secretion of proinflamma-
tory cytokines  [46] . LRRK2 expression is elevated in in-
testinal tissue of CD patients, and LRRK2-deficient cells 
are impaired in killing of intracellular bacteria  [47] , which 
suggests a possible role for LRRK2 in CD pathogenesis.
 ATG16L1, Interacting Molecules, and Paneth Cell 
Function 
 ATG16L1 represents a key molecule within the au-
tophagy network which is responsible for subcellular lo-
calization of the autophagy machinery  [48] . Presence of 
the SNP rs2241880 within the gene locus encoding 
 ATG16L1 results in substitution of threonine by alanine 
(T300A) and has been strongly associated with an in-
creased risk for developing CD  [24] . Recent studies dem-
onstrated that the presence of the CD-associated 
 ATG16L1 variant results in increased numbers, pro-
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longed survival, and elevated replication of intracellular 
bacteria  [42, 43] and consequently elevated secretion of 
the proinflammatory cytokines TNF and IL-6, which pro-
mote inflammatory conditions in the intestine  [49] . Pres-
ence of the ATG16L1 variation obviously only affects the 
extent of autophagy following activation, while basal lev-
els of autophagy remain unaffected. A recent study dem-
onstrated that CD patients featuring the ATG16L1 varia-
tion exhibit impaired antigen uptake and processing as 
well as a defective interaction between DCs and IECs in 
the intestine  [50] . In a study using mice lacking the con-
served coiled-coil domain of ATG16L1, increased inflam-
masome activation in response to PAMPs causing en-
hanced secretion of IL-1β and IL-18 was found and the 
mice were more susceptible to DSS-induced colitis  [51] . 
Recent studies identified a role for microRNAs in down-
regulating ATG16L1 and autophagy resulting in pro-
longed bacterial persistence  [52, 53] .
 ATG16L1 seems to exert a close functional correlation 
with other IBD susceptibility genes, such as NOD2 or 
PTPN2, in regulating autophagy. In DCs, NOD2-mediat-
ed autophagy is crucial for handling of invading bacteria 
as well as for antigen presentation and the induction of 
antigen-specific CD4+ T-cell responses via MHC class II 
molecules. DCs from CD patients carrying either the CD-
associated ATG16L1 or NOD2 variations are defective in 
autophagosome formation, bacterial trafficking, and an-
tigen presentation  [42] . As a possible mechanism, NOD2 
is crucial for the initiation of autophagy by recruiting 
 ATG16L1 to the cell membrane at the site of bacterial en-
try. Cells featuring CD-associated NOD2 polymorphisms 
are unable to direct ATG16L1 to the plasma membrane 
and are deficient in handling of invading bacteria  [43] . 
Presence of the CD-associated ATG16L1 variant resulted 
in increased secretion of the proinflammatory cytokines 
IL-1β and IL-6 from peripheral blood mononuclear cells 
of CD patients in response to stimulation with NOD2 li-
gands  [54] . These observations strongly suggest that 
NOD2 as well as autophagy play a key role for the innate 
immune system and present the functional mechanism 
how dysfunction of autophagy could essentially contrib-
ute to the onset of chronic intestinal inflammation. A fur-
ther close functional correlation exists between PTPN2, 
ATG16L1, NOD2, and autophagy in general. PTPN2 ex-
pression is, at least partially, regulated by ATG16L1 and 
NOD2. At a functional level, PTPN2 is involved in NOD2-
mediated autophagy, since presence of the CD-associated 
PTPN2 variations results in impaired autophagosome 
formation and is associated with decreased expression of 
a number of autophagy genes, including IRGM and 
 ATG16L1  [27, 44] . Of note, a further protein tyrosine 
phosphatase, namely PTPN22, has also been demonstrat-
ed to regulate NOD2-mediated autophagy  [29] .
 Besides its role in the handling of invading pathogens, 
ATG16L1 has been critically associated with the function 
of Paneth cells located within the crypts of Lieberkühn in 
the small intestine. Paneth cells represent a specialized 
epithelial cell type, which is important for the secretion 
of antimicrobial factors into the intestinal lumen via 
the production and secretion of characteristic cytoplas-
mic granules. In particular, hypomorphic ATG16L1 
 (ATG16L1 HM ) mice lack the antibacterial enzyme lyso-
zyme in the mucus of ileal sections, and lysozyme was 
diffusely detectable in a number of Paneth cells in 
 ATG16L1 HM mice accompanied by aberrant, disorga-
nized granules as well as decreased numbers of granules 
 [55] . Paneth cells from ATG16L1 HM mice further re-
vealed increased expression of proinflammatory mole-
cules, such as the adipocytokines leptin and adiponectin 
 [55] . Of special interest, Paneth cells derived from CD 
patients homozygous for the ATG16L1 CD risk allele fea-
ture similar abnormalities in Paneth cell morphology and 
granule secretion as ATG16L1 HM mice and endoplasmic 
reticulum stress even during quiescent CD-associated 
bacterial persistence in the intestine  [55, 56] . Interesting-
ly, all of the mentioned abnormalities in Paneth cell mor-
phology and function were absent when ATG16L1 HM 
mice were raised in an enhanced barrier facility, but could 
be completely introduced again following infection of the 
ATG16L1 HM mice with the murine norovirus strain CR6 
for 7 days, which indicates a critical role for a virus-plus-
susceptibility gene interaction  [57] . ATG16L1 HM mice 
only displayed a severe intestinal injury response to DSS 
treatment when they were infected with CR6 at least 7 
days before DSS administration, but not in the absence of 
the virus or when the virus infection occurred at the same 
time as the DSS treatment initiation. These observations 
suggest that virus-plus-susceptibility gene interactions in 
addition to environmental factors and commensal bacte-
ria are critically involved in the pathogenesis of chronic 
intestinal inflammation. 
 IRGM 
 Several variations within the IRGM gene locus are as-
sociated with CD, e.g. the coding region of IRGM, a 20-kb 
deletion polymorphism upstream of the IRGM transcrip-
tional start site, affects several transcription factor bind-
ing sites and hereby impairs IRGM expression levels and 
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the promoter region or the 5 ′ -untranslated region of 
IRGM  [24, 58, 59] . Reduced expression of IRGM seems 
to be responsible for the decreased function of IRGM and 
a subsequent impairment in autophagy, which suggests 
that a certain level of IRGM protein is necessary for prop-
er protein function. The necessary threshold level can ob-
viously not be reached in the presence of the CD-associ-
ated polymorphisms and lower levels of IRGM expres-
sion have been detected in lymphocytes from CD patients 
 [58] . Interestingly, a recent study demonstrated that the 
microRNA family, miR-196, which is overexpressed in 
the inflamed intestinal epithelium of CD patients, causes 
downregulation of the protective IRGM variant, but does 
not affect levels of the disease-associated variant. The re-
sulting decrease in IRGM expression levels contributes to 
impaired autophagy and enhanced intracellular bacterial 
replication  [60] . It has been shown that functional IRGM1 
plays a key role in regulating the maturation of pathogen-
containing vacuoles, as well as the adhesion and motility 
of activated macrophages. Consequently, IRGM1 defi-
ciency results in increased susceptibility of mice to patho-
gens and finally systemic infection  [61–63] . IRGM is also 
crucial for IFN-γ-mediated autophagy and the elimina-
tion of intracellular  Mycobacterium tuberculosis from hu-
man macrophages  [64] . siRNA-induced knockdown of 
IRGM in human cells results in a defect in the autophagy 
machinery favoring the persistence of bacteria resulting 
in increased proinflammatory responses  [49, 65] . Inter-
estingly, IRGM-deficient mice featured aberrant Paneth 
cell morphology and localization, which is associated 
with impaired autophagy and increased susceptibility to 
DSS-induced colitis  [66] . 
 Conclusion 
 Taken together, available data demonstrate that ap-
propriate response and early host defense against invad-
ing bacteria is crucial to maintain tolerance towards com-
mensal bacteria. If the mechanisms of early removal of 
invading bacteria are disturbed, this leads to a loss of tol-
erance and a full-blown adaptive immune reaction, which 
is mounted against the usually harmless commensal flora. 
Additionally, a number of studies clearly provide evi-
dence for the involvement of dysfunctional autophagy in 
the pathogenesis of CD. Dysfunction of autophagy caused 
Nontolerogenic immune response to microbial
(commensal-) and food antigens 
 
Chronic inflammation 
Food antigens PAMPs 
Toxins 
NOD2, PTPN2 
ATG16L1, IRGM  
Tr  
IL - 10 
TGF - β 
Th2 Th1 
Macrophages/  
DC   
IL - 12 
IL - 18 
TNF 
IFN - γ 
NF - κ B 
Proinflammatory Anti-inflammatory  
Barrier defect
Environmental/
invironmental
factors  
  
Genetic
susceptibility
 
Dysregulated
immune response
Chronic intestinal
inflammation
Bacteria 
IL - 17 
Co
lo
r v
er
si
on
 a
va
ila
bl
e 
on
lin
e
 Fig. 1. CD pathogenesis: an epithelial bar-
rier defect favors the invasion of commen-
sal and pathogenic bacteria, food antigens, 
and toxins into the gut mucosa. The pres-
ence of genetic variations, such as in au-
tophagy-related genes or pattern recogni-
tion receptors, contributes to the barrier 
defect and causes an impaired immune re-
sponse. Hereby, alterations in tolerance 
mechanisms affecting the innate and adap-
tive immune system as well as in autophagy 
can be observed. Of particular interest 
hereby seems to be CD-specific alterations 
in intestinal macrophages. The aberrant 
immune response results in an imbalance 
between pro- and anti-inflammatory cyto-
kines finally establishing the onset of 
chronic intestinal inflammation. 
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by genetic variations within CD susceptibility genes re-
sults in defective handling of intracellular and invading 
bacteria as well as aberrant Paneth cell function and un-
controlled secretion of proinflammatory cytokines and 
thus in increased susceptibility to bacterial infection and 
the onset of colitis. However, more and more evidence 
suggests a close functional correlation between loss-of-
tolerance and defective autophagy in CD patients, and all 
of these effects can be observed during human CD ( fig. 1 ). 
Therefore, most likely, the onset of CD is dependent on 
both a loss of tolerance as well as a dysfunction of autoph-
agy, which finally results in the onset of chronic intestinal 
inflammation in humans.
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